

# Sulfadoxine + pyrimethamine

NOT RECOMMENDED AS AN  
ESSENTIAL MEDICINE

Section: 6. Anti-infective medicines > 6.5. Antiprotozoal medicines > 6.5.3. Antimalarial medicines > 6.5.3.1. Antimalarial medicines > Medicines for curative treatment

|                          |   |                  |                    |
|--------------------------|---|------------------|--------------------|
|                          |   | EMLc             | ATC codes: P01BD51 |
| Indication               | Malaria due to Plasmodium vivax   | ICD11 code: 1F81 |                    |
| INN                      | Sulfadoxine + pyrimethamine   |                  |                    |
| Medicine type            | Chemical agent  |                  |                    |
| List type                | Core (EML)<br>(EMLc)  |                  |                    |
| Additional notes         | Only in combination with artesunate 50 mg   |                  |                    |
| Formulations             | Oral > Solid: 500 mg + 25 mg tablet   |                  |                    |
| EML status history       | First added in 1979 (TRS 641)<br>Changed in 1987 (TRS 770)<br>Changed in 2003 (TRS 920)<br>Changed in 2007 (TRS 946)<br>Changed in 2007 (TRS 950)<br>Removed in 2025 (TRS 1064) |                  |                    |
| Sex                      | All   |                  |                    |
| Age                      | Also recommended for children   |                  |                    |
| Therapeutic alternatives | The recommendation is for this specific medicine  |                  |                    |
| Patent information       | Patents have expired in most jurisdictions<br>Read more <a href="#">about patents</a> .   |                  |                    |
| Wikipedia                | <a href="#">Sulfadoxine + pyrimethamine</a>   |                  |                    |
| DrugBank                 | <a href="#">Sulfadoxine</a> ,<br><a href="#">Pyrimethamine</a>  |                  |                    |

## Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the deletion of sulfadoxine + pyrimethamine tablets from the EML and EMLc for the curative treatment of malaria, given the recommendation to add co-packaged artesunate and sulfadoxine + pyrimethamine to the EML and EMLc for this indication.

